GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » Price-to-Free-Cash-Flow

Daxor (DXR) Price-to-Free-Cash-Flow

: N/A (As of Today)
View and export this data going back to 1992. Start your Free Trial

As of today (2024-04-19), Daxor's share price is $9.75. Daxor's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.81. Hence, Daxor's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Daxor's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Daxor's highest Price-to-Free-Cash-Flow Ratio was 28.62. The lowest was 1.56. And the median was 13.10.

DXR's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 31.21
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Daxor's Free Cash Flow per Share for the six months ended in Dec. 2023 was $-0.16. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.81.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -8.30% per year.

During the past 13 years, Daxor's highest 3-Year average Free Cash Flow per Share Growth Rate was 61.80% per year. The lowest was -109.40% per year. And the median was -22.80% per year.


Daxor Price-to-Free-Cash-Flow Historical Data

The historical data trend for Daxor's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daxor Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.31 - - - -

Daxor Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Daxor's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daxor Price-to-Free-Cash-Flow Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Daxor's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Daxor's Price-to-Free-Cash-Flow falls into.



Daxor Price-to-Free-Cash-Flow Calculation

Daxor's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=9.75/-0.807
=N/A

Daxor's Share Price of today is $9.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Daxor's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.81.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Daxor  (NAS:DXR) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Daxor Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Daxor's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Daxor (DXR) Business Description

Traded in Other Exchanges
Address
109 Meco Lane, Oak Ridge, TN, USA, 37830
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Executives
Robert J Michel officer: CHIEF FINANCIAL OFFICER C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh director 71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers director DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer director 2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson officer: V.P./BUSINESS DEVELOPMENT 180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh director, officer: CHIEF SCIENTIFIC OFFICER DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh officer: President 615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh other: FOUNDER 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan officer: Corporate Secretary 259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe director 6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens director 200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson director P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom officer: Vice President 3244 BLACK FOX ROAD, WASHBURN TN 37888

Daxor (DXR) Headlines

From GuruFocus